Phase II Study of Weekly Docetaxol Combined With Cisplatin and 5-Fu in Patients With Advanced Gastric Cancer
Recently,in a multi-center, open-label randomized phase III study (V325), compared to the
control arm of CF regimen, DCF showed higher efficacy in terms of response rate, time to
progression and overall survival. But the regimen had increased grade 3-4 neutropenia (82%
vs 57%) and febrile neutropenia infection (29% vs 12%). We began to study on weekly DCF in
the patients with advanced gastric cancer to evaluate the efficacy no less than that of
3-week' regimen.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate, overall survival
2-6 months
Yes
Jin Li, PhD
Principal Investigator
Fudan University
China: Ethics Committee
DCF-AGC
NCT00568971
April 2007
June 2008
Name | Location |
---|